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Abstract Monoclonal antibodies (mAb) are revolutionising
the treatment of many different diseases. Given their differing
mode of action compared to most conventional chemothera-
peutics and small molecule inhibitors, they possess the poten-
tial to be independent of common modes of treatment resis-
tance and can typically be combined readily with existing
treatments without dose-limiting toxicity. However, treat-
ments with mAb rarely result in cure and so a full understand-
ing of how these reagents work and can be optimised is key
for their subsequent improvement. Here we review how an
understanding of the biology of the inhibitory Fc receptor,
FcγRIIB (CD32B), is leading to the development of improved
mAb treatments.
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Introduction
Fc gamma receptors (FcγRs) constitute a family of receptors
for Immunoglobulin G (IgG) molecules. There are six FcγR
family members in humans (FcγRI (CD64); FcγIIA (CD32A);
FcγRIIB (CD32B); FcγRIIC (CD32C); FcγRIIIA (CD16A)
and FcγRIIIB (CD16B)) and four in mice (FcγRI, FcγRIIB,
FcγIII and FcγRIV), with known variations in their cellular
expression patterns [1] and affinities for monomeric IgG [2].
CD32B is the only inhibitory member of the FcγR family in
mice and humans, and binds to monomeric IgGmolecules with
a low affinity [2]. It is expressed by B cells and myeloid cells at
variable levels depending on the cell subtype and activation
state [1]. In addition, CD32B is expressed on the surface of B
cell leukaemia/lymphoma cells [3]. Two isoforms of CD32B
exist in mouse and man, CD32B1 and CD32B2 [4, 5]; differ-
ences in the cytoplasmic domain of the latter results in a greater
propensity to internalise [4].
Monoclonal antibodies (mAbs) represent an established
treatment paradigm for a number of diseases including cancer,
and either aim to induce target cell destruction or immune cell
activation, such as in the case of anti-CD20 [6] or anti-CD40
[7, 8] mAbs, respectively. Following binding to their cognate
antigens, mAbs may engage Fc gamma receptors (FcγR) on
the surface of immune cells. To this end, the use of FcγR
knockout mice [9, 10], and more recently human FcγR trans-
genic [11] or Bhumanised^ mice [12] has provided over-
whelming evidence for Fc-FcγR engagement being central
to the mechanism of action of most mAb therapies.
Although less direct evidence is available in humans, FcγR
polymorphisms associated with greater affinities for the Fc
region of IgG have been associated with favourable therapeu-
tic responses and autoimmune disease susceptibility in some
cases (reviewed in [13]).
Intriguingly, it has been shown that engagement of the
inhibitory CD32B may be either detrimental [3, 9] or benefi-
cial [7, 8] to therapeutic efficacy depending on the type of
mAb and context, as will be discussed below.
CD32B and Regulation of Immune Responses
The physiological function of CD32B is to regulate the acti-
vation state of the expressing cell through interaction with
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other cell surface receptors. In B cells, co-ligation of the B cell
receptor (BCR) with CD32B on the same cell (in cis) via
antibody-coated antigen (immune complex), provides a mech-
anism to limit activation, proliferation and/or antibody secre-
tion [14]. Moreover, CD32B has been shown to provide a
threshold for activation of cells co-expressing activatory
FcγRs and CD32B [15]. For example, CD32B−/− macro-
phages produced more robust calcium (Ca2+) flux following
surface ligation of activatory FcγR and mediated greater
phagocytosis in comparison to wild type macrophages.
The nature of CD32B inhibitory signalling has recently
been reviewed elsewhere [16]. Briefly, early work showed that
a 13 amino acid sequence in the cytoplasmic domain of
CD32B, containingwhat is now known as an immunoreceptor
tyrosine-based inhibitory motif (ITIM), was responsible for
the inhibition of Ca2+ flux following BCR-CD32B co-ligation
in B cells [17]. Later work identified that the recruitment of the
SH2-domain containing 5′-inositol phosphatase SHIP-1 to
this motif is required [18]. SHIP-1 is able to down-regulate
activatory receptor signalling in several ways but central to its
function is the dephosphorylation of membrane phosphatidyl
inositol-3,4,5-trisphosphate (PIP3) to phosphatidyl inositol-3,
4-bisphosphate (PIP2); preventing the recruitment of plekstrin
homology (PH)-domain containing signalling proteins such as
Btk to the cell membrane [19].
However, it is becoming clear that the intracellular,
ITIM-containing domain of CD32B is not always required
for its inhibitory functions. One example is the intracellu-
lar region-independent, transmembrane region-dependent
clustering of the BCR and CD19 following BCR-CD32B
co-ligation, which was observed in imaging studies [20].
Further still, there is evidence that CD32B is not the only
FcγR capable of mediating inhibitory signalling, with in-
hibitory ITAM signalling (ITAMi) being observed down-
stream of activatory FcγR ligation in some circumstances
(reviewed in [16]).
The role of CD32B in preventing excessive immune
responses resulting in autoimmune disease has recently
been reviewed elsewhere [21]. However, a CD32B poly-
morphism associated with autoimmune disease that re-
sults in an I232T amino acid change in the transmem-
brane region of CD32B is noteworthy as it has provided
insight into the biology of CD32B [22, 23]. Functionally,
this polymorphism has been linked to reduced CD32B
function and hence greater ‘activatory’ signalling. In B
cells, 232 T CD32B was less able to inhibit Ca2+ flux
and downstream signalling following BCR-CD32B
crosslinking [23]. This was also observed in transfected
macrophage cell lines following activatory FcγR (CD64)
crosslinking, and monocyte derived macrophages from
232 T donors had a more activated phenotype and more
readily phagocytosed antibody-opsonised bacteria [22].
The mechanism responsible for this has been shown to
be reduced localisation of CD32B 232 T into lipid rafts
[22, 23]. Intriguingly, studies have suggested that this
polymorphism, despite being associated with an in-
creased incidence of systemic lupus erythematosus, may
provide a selective advantage in areas affected by malar-
ia [24].
In addition to effects on immune responses and propensity
to disease, CD32B is able to regulate IgG-based mAb thera-
peutics in several ways (Fig. 1).
CD32B-Mediated Regulation of Monoclonal Antibody
Efficacy
The seminal study performed by Clynes et al. demonstrated
conclusively that FcγR regulate the activity of so-called di-
rect-targeting mAb in the setting of tumour therapy. These
authors showed the absence of therapeutic responses in
activatory FcγR-deficient (γ chain −/−) mice and conversely
an improvement in mice lacking CD32B [9]. Given this im-
provement in CD32−/−mice and the fact that FcγRs other than
CD16A cannot normally be detected on the surface of natural
killer (NK) cells [1] these observations have been used as
evidence against a role for NK cells in the mechanism of
action of therapeutic mAbs. As macrophages co-express both
activatory FcγRs and CD32B [15], these studies indicate that
loss of CD32B may increase effector function (phagocytosis)
in vivo, as has been shown in vitro [15], and therefore a role for
these effectors in the mechanism of action of therapeutic
mAbs. Notably, the anti-tumour potential of tumour-
targeting mAbs has been shown to be abolished in mice de-
pleted of macrophages and other phagocytes [25]. Moreover,
convincing intravital microscopy studies have also recently
provided direct evidence for a role of macrophages in vivo
[26, 27]. Therefore, despite evidence from human peripheral
blood mononuclear cell (PBMC) assays indicating the impor-
tance of NK cells following mAb therapy in some settings, the
growing consensus in the field is that macrophages may have
a more prominent role in the mechanism of action of thera-
peutic mAbs than first thought.
IgG antibody isotypes have varying affinities for
activatory and inhibitory FcγR. Specifically, mouse
IgG1 binds FcγRIII and FcγRII whereas mouse IgG2a
antibodies bind only weakly to FcγRII but strongly to
FcγRI and IV [10]. A ratio of relative activatory to inhib-
itory FcγR binding ability can therefore be calculated,
known as the ‘activatory: inhibitory’ (A:I) ratio, and used
to predict therapeutic efficacy [10]. Notably, in mouse
models, mouse IgG2a mAbs (high A:I) are effective in
clearing tumour cells and platelets in melanoma and idio-
pathic thrombocytopenic purpura models, respectively,
whereas mouse IgG1 mAbs (low A:I) result in poorer
depletion [10]. In humans, the distinction is less clear,
although human IgG1 and 3 are perhaps most equivalent
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to mouse IgG2a, and able to deplete platelets in human-
ized mice expressing human FcγRs more effectively than
human IgG2 and 4 isotypes [12].
Finally, the ability of human IgG1 antibodies, which are
capable of binding to macrophage FcγRIV but not NK cell
FcγRIII, to deplete tumour cells in mouse models [28] pro-
vides further evidence for a role of macrophages over NK cells
in vivo, at least in mice.
In addition to these observations, we recently observed a
hitherto unappreciated facet of CD32B biology, relating to B
cell targets.
Antigenic Modulation of CD20: IgG Complexes
Work in our laboratory previously identified that certain
direct-targeting mAb such as the type I anti-CD20 mAb
Rituximab internalise from the surface of both malignant
and autoimmune B cells in a process termed antigenic modu-
lation, providing a potential resistance mechanism in the treat-
ment of these diseases [25].
To our surprise, further work showed that CD32B was
involved in this process [3], with modulation shown to corre-
late with the level of CD32B expression on the surface of the
Fig. 1 Means through which CD32B modulates mAb immunotherapy
and how it may be overcome. a Direct targeting mAb. Clearance of
tumour cells opsonised with anti-tumour mAbs requires interaction with
activatory FcγR on the surface of macrophages, resulting in downstream
phagocytosis of the tumour cell (i). The inhibitory FcγR CD32B may
inhibit this process, either by promoting target antigen: mAb complex
internalisation (modulation) from the target cell surface, and/or by
inhibiting activatory FcγRs on macrophages (ii). One strategy to
overcome this inhibition of target cell phagocytosis may be to target
CD32B on the target and/or effector cell with anti-CD32B mAbs (iii). b
Immunomodulatory and pro-apoptotic mAb. In contrast to (a), mAbs
which aim to induce immune cell activation (immunomodulatory
mAbs) or target cell apoptosis (pro-apoptotic mAbs) have been shown
to benefit from interactions with the inhibitory FcγR CD32B (i).
Interaction with CD32B may be limited by a low affinity for CD32B or
the availability of CD32B+ cells (ii). One approach to overcome this may
be to introduce mutations (S267E/L328F) into the constant region of
these antibodies to increase CD32B binding (iii, top). Alternatively, the
human IgG2B isotype has been shown to have greater agonisitic
properties by inducing greater target antigen clustering, independently
of CD32B binding (iii, bottom)
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lymphoma or B cell [3]. Furthermore, our results suggested
that cis interaction between the Fc portion of anti-CD20 mAb
and CD32B on the same cell was responsible for
internalisation, in a process termed antibody bipolar bridging.
Although Rituximab leads to phosphorylation of CD32B in
cis as a result of this process, it was shown that the intracellular
domain of CD32B was not required for modulation [29].
Nevertheless, such antigenic modulation is of therapeutic
relevance for several reasons. Firstly, modulation of CD20 by
type I anti-CD20 mAbs was shown to limit tumour cell killing
by mouse and human immune effector cells [28]. Secondly,
the decline in effector cell mediated killing was not observed
in the context of type II anti-CD20 mAbs, consistent with the
lack of modulation [28]. Moreover, type II anti-CD20 mAbs
led to greater B cell depletion in vivo in comparison to type I
anti-CD20 mAbs [28] and were more effective in a clinical
trial involving chronic lymphocytic leukaemia (CLL) patients
[6]. Thirdly, considering the link between CD32B expression
and antigenic modulation, the expression level of CD32B on
B cell leukaemias/lymphomas may be able to predict response
to mAb therapy. To this end, it was shown that mantle cell
lymphoma patients with greater tumour CD32B expression
had a shorter progression-free survival following Rituximab
containing immunochemotherapy [3]. Similar observations
were made in the setting of Rituximab monotherapy in follic-
ular lymphoma [30]. Finally, the modulation of type I anti-
CD20 mAbs from the cell surface may contribute to a reduc-
tion in antibody half-life [28].
Contrasting Effect of CD32B with Immune-Modulatory
and Pro-Apoptotic Antibodies
Unexpectedly, in vitro and in vivo experiments performed by
several independent research groups showed that the ability of
immune modulatory mAbs targeting the tumour necrosis fac-
tor receptor (TNFR) superfamily member CD40 required
binding to CD32B for optimal function [7, 8, 31]. These ‘ag-
onistic’ mAbs, in contrast to Rituximab in the scenario de-
scribed above, engage CD32B on a different cell than the
target (in trans) to elicit antigen presenting cell (APC) activa-
tion and subsequent adaptive immune responses [31]. As a
result, these reagents achieve most potent agonism as mouse
IgG1 antibodies due to preferential CD32B binding, in con-
trast to Rituximab which works optimally as a mouse IgG2a in
mice (see above). Similarly, pro-apoptotic mAbs targeting
death receptors such as DR-5 have shown a requirement for
CD32B binding in mouse models [32, 33]. These findings
therefore provide a model whereby CD32B can promote tar-
get antigen clustering in trans leading to target cell activation
or apoptotic signalling. However, similar to CD20:mAb anti-
genic modulation, the intracellular domain of CD32B is not
required for these clustering functions [7, 34].
Side-Effects Downstream of CD32B Engagement
Although CD32B binding may promote immune-modulatory
or pro-apoptotic mAb activity, a limitation may be an in-
creased risk for side effects. Notably, a pro-apoptotic, anti-
Fas mAb caused CD32B-dependent lethal hepatotoxicity in
mice [34]. This was proposed to be due to sinusoidal endo-
thelial cell CD32B expression. Similarly, the anti-DR-5 mAb
MD5-1 induced CD32B-dependent hepatotoxicity at high
doses in mice [33].
In a different context, the administration of an anti-CD28
human IgG4 mAb led to the hospitalisation of 6 clinical trial
participants, and their treatment for cytokine release syndrome
[35]. Studies with PBMCs have since shown that FcγRs, and
in particular CD32B, can provide a crosslinking function (in
trans) that is required to elicit potent cytokine release from
TGN1412-opsonised T lymphocytes [36]. Furthermore, in
these assays, a high density pre-culture is required which re-
sults in a large upregulation of CD32B on the monocytes [37].
It is these CD32Bhigh monocytes, (as well as CD32B+ B cells
in sufficient number), that are capable of clustering the Fc
region of TGN1412 bound to target CD28 antibodies on the
surface of T cells and promoting inflammatory cytokine re-
lease. The promotion of target antigen clustering by CD32B
has therefore been proposed as a potential mechanism to ex-
plain the severe side effects observed in this trial.
Although details of the potential requirement for CD32B in
this setting in vivo are still being elucidated, these studies
highlight an underappreciated role of human IgG molecules,
including IgG4, to bind to CD32Bwhen present as an immune
complex, as has been previously reported [38]. This empha-
sises the need to consider alternative assays other than the
assessment of monomeric IgG-FcγR interactions via surface
plasmon resonance in the screening of candidate therapeutic
mAbs.
Therapeutic Strategies
As discussed above, CD32B may provide beneficial or detri-
mental contributions to the efficacy of therapeutic mAbs de-
pending on the context. Treatments are therefore being devel-
oped to either abrogate the inhibitory functions of CD32B,
harness the ability of CD32B to promote mAb: target cluster-
ing and downstream signalling, or overcome the requirement
for CD32B binding (Fig. 1).
Anti-CD32B Antibodies
One approach to inhibit CD32B function is to develop
mAbs targeting this receptor. Generation of both anti-
mouse [39] and anti-human [40, 41] CD32B-specific
mAbs has been achieved, the latter, despite the close
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similarity between the extracellular domains of the
activatory FcγR CD32A and CD32B.
Anti-mouse CD32B mAbs were identified that induced or
prevented the phosphorylation of the CD32B cytoplasmic re-
gion, so called agonistic or antagonistic mAbs, respectively
[39]. Despite mediating direct cell death [39] and antibody-
dependent cell-mediated phagocytosis (ADCP) [42], studies
of anti-CD32B antibodies in mice were thwarted by rapid
internalisation and loss of antibodies from the circulation
[42], similar to anti-CD20 modulation (see above), although
this was not applicable to the human system.
Anti-human CD32B mAbs were also generated and shown
to be either agonistic or antagonistic with regards CD32B
phosphorylation [41]. A candidate antagonistic mAb (6G11)
was taken forward for further investigation. Similar to previ-
ous studies of anti-human CD32B [40], this study confirmed
the ability of anti-CD32B mAbs to mediate direct cell death,
antibody-dependent cell-mediated cytotoxicity (ADCC) and
ADCP in vitro. Anti-CD32B N297Q mAbs, which cannot
interact with FcγRs through their Fc, were previously shown
not to induce ADCC or ADCP in vitro [40]. However,
CD32B-specific N297Q mAbs were capable of reducing an-
tigenic modulation induced by Rituximab (see above), which
corresponded to an increase in effector-mediated killing [41].
This suggests that anti-CD32B mAbs may also function in an
Fc-independent manner to inhibit CD20:mAbmodulation and
maintain anti-CD20:mAb Fc region recognition by effector
cells. Inhibition of CD32B co-ligation with activatory FcγR
on immune cells is another possible Fc-independent function.
This study, in comparison to previous studies of anti-
human CD32B [40], used human CD32B transgenic mice that
lack the endogenous mouse receptor [41]. Key findings in-
clude the ability of N297Q mAbs to enhance B cell depletion
only when combined with Rituximab in vivo, and the greater
tumour depletion observed in mice xenografted with primary
CLL cells when treated with a Rituximab plus anti-CD32B
mAb in combination.
Considering the expression of CD32B on both the surface
of B cell leukaemia/lymphoma cells and immune effector
cells, it is at present difficult to distinguish the relative contri-
bution of inhibition of tumour cell antigenic modulation ver-
sus blocking of inhibitory CD32B signalling in immune cells
to the therapeutic effects. Our current studies aim to dissect
these various aspects.
Antibody Fc Region Engineering
One avenue to increase the efficacy of therapeutic mAbs has
been to engineer their Fc regions to have altered affinities for
FcγRs; typically higher and lower affinities to activatory and
inhibitory FcγRs, respectively. This may be achieved by mu-
tagenesis [43] or by altering the glycan groups attached to
residue N297 in the Fc region of antibodies [44]. Recently,
specific mutations of the mAb Fc backbone which selectively
increase binding affinities to individual human FcγRs have
been linked to distinct effector mechanisms [11], contributing
to our understanding of mAb mechanisms of action.
Antibody variants, such as S239D/I332E/A330L, may be
selected which have improved binding to activatory over in-
hibitory FcγRs, and hence activatory: inhibitory ratios [43],
which may reduce the inhibition of effector cell signalling by
CD32B. In contrast, mutations have also been considered to
increase mAb Fc region binding to CD32B, such as in the
context of autoimmune disease treatment [45]. One particular
polymorphism (S267E/L328F or SE/LF) is known to increase
the Fc region binding affinity of human IgG1 to human
CD32B by 430-fold, and binding to CD32B-transfected cells
by 310-fold [45]. Consequently, the SE/LF mutant on an anti-
CD19 backbone was able to limit B cell activation down-
stream of CD79b stimulation. Although this approach would
likely dampen the efficacy of tumour-targeting mAbs which
require activatory FcγR binding as opposed to CD32B for
function, mutating these residues has been shown to augment
the efficacy of mAbs targeting TNFR superfamily members
which benefit from CD32B engagement (see above).
Specifically, the treatment of human CD32B transgenic mice
with human IgG1 anti-DR5 antibodies with the S267E muta-
tion resulted in greater tumour regression and/or survival in
comparison to unmodified mAb, which corresponded with
enhanced tumour cell apoptosis in vitro [33]. Similarly, an
anti-CD40 S267E/L328F human IgG1 mAb induced greater
B cell activation and proliferation in vitro [31]. Moreover,
human IgG1 anti-CD40 S267E was more agonistic in human
CD32B-transgenic mice, with favourable tumour depletion
and prolonged survival [8].
However, strategies to increase the affinity of the Fc por-
tion of mAbs for CD32B may be limited by an increased
potential for side-effects (see above). In particular, despite
having favourable efficacy, the S267E version of a human
IgG1 anti-DR5 mAb resulted in a significant increase in liver
enzyme release [33].
Afucosylation, (removal of the fucose groups attached to
the N297 glycan of antibodies), is known to increase Fc bind-
ing to the activatory FcγR CD16A and consequently enhance
effector-mediated killing (ADCC) [44]. Although the
glycomodified (afucosylated) type II anti-CD20 mAb
obinutuzumab combined with chlorambucil chemotherapy
was more efficacious in comparison with rituximab plus che-
motherapy in clinical trials [6], results from in vitro and in vivo
studies of a non-glycomodified version of obinutuzumab sug-
gest that the superiority of type II anti-CD20 mAbs is most
likely a result of their type II nature rather than
glycomodification [28]. For example, it should be considered
that the relatively less antigenic modulation mediated by type
II anti-CD20 mAbs may be responsible for the differences in
efficacy observed in patients.
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CD32B-Independent mAb: Antigen Clustering
Although agonistic anti-CD40 mAbs required CD32B
binding in mice (see above), the affinity of human IgG1
to CD32B is low, at least in monomeric form [2], and
enhancing CD32B binding may increase hepatotoxicity
[34]. Therefore, designing agonistic mAbs that avoid or
overcome the requirement for CD32B binding may be
desirable. Intriguingly, the human IgG2 isoform IgG2B
has recently been shown to cluster target antigens and
promote cell signalling and activation independently of
CD32B binding [46]. Considering the fact that monomer-
ic IgG2 has the lowest affinity for CD32B out of all hu-
man IgG isotypes [2], the use of this isotype may also
provide an opportunity to limit the side effects observed
with agonistic antibodies that bind to CD32B in mice (see
above).
Future Directions
The beneficial and detrimental influences of CD32B on mAb
therapeutic efficacy have been discussed, as well as potential
therapeutic strategies to take advantage of CD32B binding, or
inhibit CD32B function. The pre-clinical development of anti-
CD32B mAbs has provided the background for a clinical trial
of a lead candidate (BI-1206) due to begin later this year.
However, unanswered questions include: why targeting
CD32B with different mAbs leads to different biological out-
comes (CD32B phosphorylation or not), and specifically how
structural changes or clustering in the cell membrane follow-
ing antibody: CD32B interactions result in these differences.
Finally, although this review has largely focussed on the
context of B cell targets, there is also evidence that CD32B is
expressed by other target cells (e.g. metastatic melanoma
cells), and a mechanism whereby CD32B inhibits ADCC of
these cells has also been proposed [47] providing the potential
for therapeutic blocking of CD32B in this setting. Finally, it
remains a possibility that blocking CD32B on effector cells
may be useful in additional settings where other deleting
mAbs are being used but where CD32B is not expressed on
the target cell.
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